CAJ | 학술논문

目的探讨非小细胞肺癌术后患者应用吉西他滨联合榄香烯辅助化疗疗效及安全性分析.方法选取2009年3月至2012年3月在我院接受辅助化疗的86例非小细胞肺癌术后患者为研究对象,按随机数字表法分为对照组和观察组,2组患者均给予GP方案,吉西他滨1.0 g/m2+顺铂80.0 g/m2,观察组加用榄香烯500.0 mg/m2静脉滴注,3周/疗程,2组均连续治疗4个疗程;2组患者均定期复查,观察2组疗效及不良反应.结果对照组和观察组的中位随访时间分别为12.83个月、14.67个月;对照组和观察组的无病生存期分别为7.8个月、9.1个月,观察组总有效率为44%高于对照组的35%,2组比较差异无统计学意义(χ2=0.778,P>0.05);观察组术后1年内复发3例,2年内复发5例,复发率为19%,对照组患者术后1年内复发2例,2年内复发8例,复发率为23%,2组比较差异无统计学意义(χ2=0.281,P>0.05);与治疗前比较,2组治疗后KPS评分均显著增加(t=11.428、4.666,P<0.05);治疗后观察组KPS评分显著高于对照组(t=5.997,P<0.05);观察组出现Ⅲ~Ⅳ级白细胞减少发生率21%、Ⅲ~Ⅳ级中性粒细胞减少发生率19%、Ⅲ~Ⅳ级血小板减少发生率14%,与对照组(49%、51%、37%)比较,差异均具有统计学意义(P<0.05).结论非小细胞肺癌术后患者应用吉西他滨联合榄香烯辅助化疗疗效显著,可降低不良反应发生率,提高患者生活质量.
목적 탐토비소세포폐암술후환자응용길서타빈연합람향희보조화료료효급안전성분석.방법 선취2009년3월지2012년3월재아원접수보조화료적86례비소세포폐암술후환자위연구대상,안수궤수자표법분위대조조화관찰조,2조환자균급여GP방안,길서타빈1.0 g/m2+순박80.0 g/m2,관찰조가용람향희500.0 mg/m2정맥적주,3주/료정,2조균련속치료4개료정;2조환자균정기복사,관찰2조료효급불량반응.결과 대조조화관찰조적중위수방시간분별위12.83개월、14.67개월;대조조화관찰조적무병생존기분별위7.8개월、9.1개월,관찰조총유효솔위44%고우대조조적35%,2조비교차이무통계학의의(χ2=0.778,P>0.05);관찰조술후1년내복발3례,2년내복발5례,복발솔위19%,대조조환자술후1년내복발2례,2년내복발8례,복발솔위23%,2조비교차이무통계학의의(χ2=0.281,P>0.05);여치료전비교,2조치료후KPS평분균현저증가(t=11.428、4.666,P<0.05);치료후관찰조KPS평분현저고우대조조(t=5.997,P<0.05);관찰조출현Ⅲ~Ⅳ급백세포감소발생솔21%、Ⅲ~Ⅳ급중성립세포감소발생솔19%、Ⅲ~Ⅳ급혈소판감소발생솔14%,여대조조(49%、51%、37%)비교,차이균구유통계학의의(P<0.05).결론 비소세포폐암술후환자응용길서타빈연합람향희보조화료료효현저,가강저불량반응발생솔,제고환자생활질량.
Objective To investigate the effect and safety of using gemcitabine and elemene in patients with non-small cell lung cancer (NSCLS) after the operation. Methods Eighty-six patients with NSCLC, who received ad-juvant chemotherapy after the operation in our hospital between March 2009 and March 2012, were included as the subjects in the study. All patients were randomly divided into the control group and study group. Both groups were treated with GP protocol, gemcitabine 1.0 g/m2+ cisplatin 80.0 g/m2, and the study group was added with elemene 500.0 mg/m2 intravenously for three weeks/course. Both groups were treated for continuous 4 courses. All patients were regularly examined. The effect and adverse reactions of the two groups were observed. Results The median follow-up time in the control group and the study group were 12.83 months and 14.67 months, respectively. The disease-free survival in the control group and the study group were 7.8 months and 9.1 months. The total effective rate in the study group was 44%, which was higher than 35%in the control group, and there was no significant difference between the two groups (χ2=0.778, P>0.05). In the study group, there were 3 cases of recurrence at 1 year after the operation, and 5 cases of recurrence at 2 years after the operation, with the , recurrence rate of 19%. In the control group, there were 2 cases of recurrence at 1 year after the operation, and 8 cases of recurrence at 2 years after the operation, with the recurrence rate of 23%. There was no statistical difference between the two groups (χ2=0.281, P>0.05). The KPS scores in the two groups were significantly increased after the treatment compared with those before the treatment ( t=11.428, 4.666, P<0.05). The KPS score in the study group was significantly higher than that in the control group after the treatment (t=5.997, P<0.05). The incidence of grade Ⅲ-Ⅳ leukopenia, neutropenia, and thrombocytopenia in the study group were 21%, 19%and 14%, with statistical significance compared with those in the control group (49%, 51% and 37%), respectively (P<0.05). Conclusion The effect of using gemcitabine and elemene for adjuvant chemotherapy in patients with NSCLC after the operation is significant, which can decrease the incidence of adverse reactions and improve the quality of life of patients.